Efficacy and Safety of Dolutegravir With Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy oIMPAACT 2010/VESTEDTHORN: A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial

被引：0
|
作者：
Aquino, Marcella
机构：
来源：
PEDIATRICS | 2021年 / 148卷
关键词：
D O I：
10.1542/peds.2021-053843YYYY
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [31] Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
    Ruane, P. J.
    Clarke, A.
    Post, F. A.
    Schembri, G.
    Jessen, H.
    Trottier, B.
    Bergin, C.
    Molina, J-M
    Wong, P.
    Ebrahimi, R.
    Brainard, D. M.
    Osinusi, A.
    Das, M.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 95 - 96
  • [32] Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, 3 trial
    Ogbuagu, Onyema
    Ruane, Peter J.
    Podzamczer, Daniel
    Salazar, Laura C.
    Henry, Keith
    Asmuth, David M.
    Wohl, David
    Gilson, Richard
    Shao, Yongwu
    Ebrahimi, Ramin
    Cox, Stephanie
    Kintu, Alexander
    Carter, Christoph
    Das, Moupali
    Baeten, Jared M.
    Brainard, Diana M.
    Whitlock, Gary
    Brunetta, Jason M.
    Kronborg, Gitte
    Spinner, Christoph D.
    LANCET HIV, 2021, 8 (07): : E397 - E407
  • [33] Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
    Scott, Rachel K.
    Yu, Yifan
    Marzinke, Mark A.
    Coleman, Jenell S.
    Hendrix, Craig W.
    Bies, Robert
    FRONTIERS IN REPRODUCTIVE HEALTH, 2023, 5
  • [34] Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data: Erratum
    D'Antoni, Michelle L.
    Andreatta, Kristen
    Chang, Silvia
    Cox, Stephanie
    Hindman, Jason T.
    Avihingsanon, Anchalee
    Martin, Hal
    VanderVeen, Laurie A.
    Callebaut, Christian
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 97 (02) : 202 - 202
  • [35] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent
    Post, Frank
    Yazdanpanah, Yazdan
    Schembri, Gabriel
    Lazzarin, Adriano
    Reynes, Jacques
    Maggiolo, Franco
    Yan, Mingjin
    Abram, Michael
    Tran-Muchowski, Cecilia
    Cheng, Andrew
    Rhee, Martin
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [36] Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial
    Glidden, David, V
    Das, Moupali
    Dunn, David T.
    Ebrahimi, Ramin
    Zhao, Yongwu
    Stirrup, Oliver T.
    Baeten, Jared M.
    Anderson, Peter L.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 (05)
  • [37] Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate-Based Single-Tablet Regimens
    Mills, Anthony M.
    Cohen, Calvin
    DeJesus, Edwin
    Brinson, Cynthia
    Williams, Scott
    Yale, Kitty L.
    Ramanathan, Srini
    Wang, Maggie H.
    White, Kirsten
    Chuck, Susan K.
    Cheng, Andrew K.
    HIV CLINICAL TRIALS, 2013, 14 (05): : 216 - 223
  • [38] Changes in metabolic parameters after switching from tenofovir disoproxil fumarate to tenofovir alafenamide among chronic hepatitis B patients: a randomized, open-label controlled trial
    Veerachit-O-Larn, Titinan
    Atthakitmongkol, Thanapat
    Teerasamit, Wanwarang
    Nimanong, Supot
    Chainuvati, Siwaporn
    Charatcharoenwitthaya, Phunchai
    Tanwandee, Tawesak
    Chotiyaputta, Watcharasak
    JOURNAL OF HEPATOLOGY, 2024, 80 : S796 - S797
  • [39] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
    Orkin, Chloe
    Molina, Jean-Michel
    Negredo, Eugenia
    Arribas, Jose R.
    Gathe, Joseph
    Eron, Joseph J.
    Van Landuyt, Erika
    Lathouwers, Erkki
    Hufkens, Veerle
    Petrovic, Romana
    Vanveggel, Simon
    Opsomer, Magda
    LANCET HIV, 2018, 5 (01): : E23 - E34
  • [40] SAFETY AND EFFICACY OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE JAPANESE PATIENTS WITH HIV-1 INFECTION
    Yajima, K.
    Yagura, H.
    Yukawa, S.
    Hirota, K.
    Ikuma, M.
    Kasai, D.
    Watanabe, D.
    Nishida, Y.
    Uehira, T.
    Shirasaka, T.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A237 - A237
12345